JPMorgan sets USD 345.00 target for Charles River Laboratories stock
Published on 10/17/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- JPMorgan analyst Casey Woodring maintained a Buy rating and set a USD 345.00 target on October 16, 2026.
- Charles River Laboratories will report third-quarter 2026 results on November 4, 2026.
- Charles River Laboratories stock was EUR 267.10 on October 16, 2026 at 8:02 p.m. CEST, down 2.23 percent versus the Tradegate close.
- Market capitalization stood at USD 14.5 billion on October 17, 2026.
JPMorgan analyst Casey Woodring maintained a Buy rating and set a USD 345.00 price target for Charles River Laboratories on October 16, 2026, according to TipRanks. Against the USD 300.15 last price on the NYSE, the target stands 14.94 percent higher. On October 16, 2026, Charles River Laboratories was last at EUR 267.10 on Tradegate at 8:02 p.m. CEST, down 2.23 percent versus the Tradegate close.
Target leaves room above the price
The JPMorgan target is the most direct valuation reference for the stock. It sits USD 44.85 above the NYSE price of USD 300.15, while the target distance remains within the corridor covered by recent analyst estimates. The rating was maintained rather than changed, so the new information is the target level and its relation to the latest US quotation.
Stock stays below the yearly high
Charles River Laboratories traded between USD 296.35 and USD 308.83 on October 16, 2026. Its 52-week range was USD 146.20 to USD 333.30, leaving the latest NYSE price 9.95 percent below the high. The company had 674,519 shares in volume during that session, compared with an average volume of 945,051 shares.
Results date sets the next marker
Charles River Laboratories has scheduled its third-quarter 2026 earnings release and conference call for November 4, 2026, according to Charles River Laboratories. The company describes its business as a contract research organization serving pharmaceutical and biotechnology clients across research models, discovery and safety assessment, and manufacturing solutions.
Comparison with peers
Charles River Laboratories (NYSE, USD): minus 2.23 percent, market capitalization USD 14.5 billion
Thermo Fisher Scientific (NYSE, USD): minus 0.93 percent, P/E 37.12, market capitalization USD 255.1 billion
IQVIA Holdings (NYSE, USD): minus 1.53 percent, P/E 33.11, market capitalization USD 43.9 billion
Price and valuation remain separate
The euro quotation and the US listing describe different trading venues, so the Tradegate price is kept separate from the NYSE quotation. The stock's market capitalization was USD 14.5 billion as of October 17, 2026, while the NYSE price remained below the USD 333.30 yearly high.
The further course of trading is shown by the continuously updated real-time quote of Charles River Laboratories stock.
Charles River Laboratories at a glance
- Company: Charles River Laboratories International, Inc.
- ISIN: US1598641074
- Ticker: CRL
- Primary exchange: NYSE
- Price Tradegate (as of October 16, 2026, 8:02 p.m. CEST): EUR 267.10
- Change versus Tradegate close: minus 2.23 percent
- Market capitalization: USD 14.5 billion (as of October 17, 2026)
- 52-week range: USD 146.20-333.30 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical - Diagnostics and Research
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
